^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit)

    i
    Other names: ERCC3, ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit, Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 3, General Transcription And DNA Repair Factor IIH Helicase Subunit XPB, Excision Repair Cross-Complementation Group 3, Basic Transcription Factor 2 89 KDa Subunit, DNA Repair Protein Complementing XP-B Cells, DNA Excision Repair Protein ERCC-3, TFIIH 89 KDa Subunit, TFIIH Subunit XPB, TFIIH P89, BTF2 P89, XPB, TFIIH Basal Transcription Factor Complex Helicase XPB Subunit, Xeroderma Pigmentosum, Complementation Group B, DNA Repair Helicase, GTF2H, RAD25, TFIIH, BTF2, TTD2, XPBC
    21d
    Somatic Mutation Profiling and Therapeutic Landscape of Breast Cancer in the MENA Region. (PubMed, Cells)
    Therapeutic annotation using OncoKB identified 223 actionable or likely oncogenic variants, highlighting potential targets for precision oncology. This study provides a comprehensive characterization of the breast cancer mutational landscape in MENA patients and offers a valuable resource for advancing genomic and therapeutic research in this demographic.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ATM (ATM serine/threonine kinase) • SF3B1 (Splicing Factor 3b Subunit 1) • MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • ERCC2 (Excision repair cross-complementation group 2) • KMT2C (Lysine Methyltransferase 2C) • RAD51C (RAD51 paralog C) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • GATA3 (GATA binding protein 3)
    |
    TP53 mutation • PIK3CA mutation • ATM mutation • PTEN mutation
    2ms
    Construction of a prediction model for hepatocellular carcinoma based on machine learning and its prognostic characteristics. (PubMed, Medicine (Baltimore))
    An online HCC mortality risk prediction model was developed using the RSF algorithm. LPL, RAET1E, RNASEH2A, GTF2H4, SCML2, and PRDM12 are potential prognostic target genes, whereas TP53 mutations are associated with clinical features that may inform the development of HCC therapy.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • GTF2H4 (General Transcription Factor IIH Subunit 4)
    |
    TP53 mutation
    3ms
    Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer. (PubMed, Eur J Med Chem)
    Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-κB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKα and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.
    Journal
    |
    ERCC2 (Excision repair cross-complementation group 2) • DDB2 (Damage Specific DNA Binding Protein 2) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
    9ms
    ERCC3 serves as a prognostic biomarker for hepatocellular carcinoma and positively regulates cell proliferation and migration. (PubMed, Discov Oncol)
    This study is the first to reveal the association between high ERCC3 expression and poor prognosis in HCC and to elucidate its immunomodulatory role in HCC. Unlike previous studies, we found that ERCC3 promotes HCC progression by regulating the inflammatory microenvironment and immune checkpoints. These findings establish a novel theoretical foundation for the development of targeted immunotherapies for HCC and provide new insights into the molecular mechanisms underlying ERCC3's role in HCC.
    Journal • IO biomarker
    |
    ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit)
    10ms
    Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma. (PubMed, Oncogene)
    Clinical association analysis of HCC cases showed GTF2H2 expression was higher in female HCC, with correlation positively with ERα expression. Taken together, the estrogen-regulated GTF2H2 may be involved in the development and sex disparity of HCC by maintaining NER-related genomic stability and affecting PAM/NF-κB signaling pathway.
    Journal
    |
    ER (Estrogen receptor) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit)
    11ms
    A Novel Platinum-Resistance-related Gene Signature in Ovarian Cancer: Identification and Patient-derived Organoids Verification. (PubMed, Curr Cancer Drug Targets)
    The platinum-resistance-related gene signature (SLC22A2, TAP1, PC, MCM3, GTF2H2, FXYD5, SUPT6H, IGKC, and MATN2) is valuable for prognosis prediction and guidance of treatment choices for OC patients.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • IGKC (Immunoglobulin Kappa Constant) • TAP1 (Transporter 1) • MCM3 (Minichromosome maintenance complex component 3) • SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    cisplatin • dasatinib • midostaurin • MK-2206 • mitomycin • metformin
    12ms
    ERCC3 Gene Associated with Breast Cancer: A Genetic and Bioinformatic Study. (PubMed, Breast J)
    The ERCC3 mutation p.Y116X may increase breast cancer risk in the Han-Chinese population. ERCC3 exhibits potential as a biomarker for the pathological diagnosis of breast cancer.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit)
    1year
    Systematic identification of pathogenic variants of non-small cell lung cancer in the promoters of DNA-damage repair genes. (PubMed, EBioMedicine)
    Our findings indicate that functional promoter variants in DDR genes, in addition to protein-truncating variants, can be pathogenic and contribute to lung cancer susceptibility.
    Journal
    |
    BRCA2 (Breast cancer 2, early onset) • RAD51B (RAD51 Paralog B) • DDB2 (Damage Specific DNA Binding Protein 2) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • ALKBH2 (AlkB Homolog 2) • APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
    1year
    Uterine sarcoma with KAT6B/A::KANSL1 fusion: a molecular and clinicopathological study on 9 cases. (PubMed, Virchows Arch)
    Of the 8 patients with available follow-up, two died of disease, 3 are currently alive with disease, and 3 have no evidence of disease. The correct recognition of tumors with the KAT6B/A::KANSL1 fusion is essential because despite the bland morphological features of most cases, these tumors have a propensity for aggressive behavior.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • TSC1 (TSC complex subunit 1) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • FANCD2 (FA Complementation Group D2) • KAT6B (Lysine Acetyltransferase 6B)
    |
    TP53 mutation • ATM mutation • PTEN mutation • NF1 mutation • TSC1 mutation • PDGFRB mutation
    1year
    The N-Terminal Region of the Transcription Factor E2F1 Contains a Novel Transactivation Domain and Recruits General Transcription Factor GTF2H2. (PubMed, Biomolecules)
    E2F1 binding enhanced the binding of GTF2H2 to target promoters depending on the integrity of the N-terminal region. Taken together, these results suggest that the N-terminal region of E2F1 contains a novel transactivation domain that mediates the activation of tumor suppressor genes, at least in part, by recruiting GTF2H2.
    Journal
    |
    ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • E2F1 (E2F transcription factor 1)
    1year
    Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population. (PubMed, Sci Transl Med)
    Next, we validated the existence of these three NAFLD molecular subtypes in an external cohort comprising 92 patients with NAFLD across three different Chinese hospitals. These findings may aid in understanding the molecular features underlying NAFLD heterogeneity, thereby facilitating clinical diagnosis and treatment strategies with the aim of preventing the development of liver cirrhosis and HCC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CCL2 (Chemokine (C-C motif) ligand 2) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    over1year
    GTF2H5 Identified as a crucial synthetic lethal target to counteract chemoresistance in colorectal cancer. (PubMed, Transl Oncol)
    The identification of SL genes that collaboratively interact with chemotherapeutic agents could provide new insights into solving the issue of chemotherapy resistance in CRC patients. And GTF2H5 wields a fundamental influence in inducing chemoresistance in CRC, which provided a potential therapeutic target for CRC.
    Journal • Synthetic lethality
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit)
    |
    5-fluorouracil • leucovorin calcium